GoodRx (NASDAQ:GDRX) Cut to “Hold” at Wall Street Zen

GoodRx (NASDAQ:GDRX) was downgraded by stock analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Sunday.

Other equities research analysts have also issued research reports about the company. UBS Group reissued a “reduce” rating on shares of GoodRx in a research note on Monday, January 5th. Barclays initiated coverage on GoodRx in a research report on Monday, December 8th. They issued an “underweight” rating and a $3.00 price objective for the company. Weiss Ratings reissued a “sell (d)” rating on shares of GoodRx in a research note on Tuesday, December 23rd. Citigroup decreased their target price on shares of GoodRx from $5.00 to $4.50 and set a “buy” rating on the stock in a research note on Friday, January 9th. Finally, JPMorgan Chase & Co. lowered their price target on shares of GoodRx from $6.00 to $5.00 and set an “overweight” rating for the company in a report on Tuesday, November 11th. Five investment analysts have rated the stock with a Buy rating, six have given a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $4.73.

GoodRx Price Performance

Shares of GoodRx stock opened at $2.56 on Friday. The company has a debt-to-equity ratio of 0.81, a quick ratio of 3.11 and a current ratio of 3.11. GoodRx has a 52-week low of $2.47 and a 52-week high of $5.81. The company has a fifty day moving average of $2.75 and a 200-day moving average of $3.66. The stock has a market capitalization of $868.95 million, a price-to-earnings ratio of 28.44, a price-to-earnings-growth ratio of 0.97 and a beta of 1.45.

GoodRx (NASDAQ:GDRX) last issued its earnings results on Tuesday, November 4th. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). GoodRx had a return on equity of 9.73% and a net margin of 3.97%.The business had revenue of $196.03 million during the quarter, compared to analysts’ expectations of $195.17 million. During the same quarter in the previous year, the business earned $0.08 EPS. GoodRx’s revenue for the quarter was up .4% compared to the same quarter last year. Equities research analysts expect that GoodRx will post 0.13 EPS for the current year.

Institutional Trading of GoodRx

Institutional investors and hedge funds have recently bought and sold shares of the stock. Quarry LP bought a new stake in GoodRx during the 3rd quarter valued at approximately $33,000. Boothbay Fund Management LLC bought a new position in shares of GoodRx in the 3rd quarter worth approximately $43,000. Shay Capital LLC purchased a new position in shares of GoodRx in the 3rd quarter valued at approximately $47,000. Cetera Investment Advisers bought a new stake in shares of GoodRx during the second quarter valued at approximately $50,000. Finally, Walled Lake Planning & Wealth Management LLC bought a new stake in shares of GoodRx during the second quarter valued at approximately $55,000. 63.77% of the stock is currently owned by hedge funds and other institutional investors.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.